OpenAlex
PricingAboutJobs
Log inGet started
Work

Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail

HTML

Year: 2010
Type: review
Source: Biochemical Pharmacology
DOI: 10.1016/j.bcp.2010.04.029
Authors: Gajanan S. Inamdar, SubbaRao V. Madhunapantula, Gavin P. Robertson
Institutions: Pennsylvania State University, Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: MAPK signaling, melanoma, BRAF mutation, RAS mutations, MAPK inhibitors, drug resistance, pathway crosstalk, combination therapy, nanotechnology drug delivery, targeted cancer therapy
SDG: Good health and well-being

Open Access status: green

Funders: Melanoma Research Foundation, National Cancer Institute
Awards: G397024791, G4937485913, Akt3 Signaling as a Therapeutic Target, Melanoma Chemoprevention by Targeting Mutant (V600E) B-Raf
OpenAlex ID: W2092286514
FWCI: 1.72
Cites: 156
Cited by: 263
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms